AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 92 min read$STAA

STAAR SURGICAL CO (STAA): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

STAAR SURGICAL CO (STAA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 September 8, 2026 STAAR Surgical Names Former CEO David Bailey as Chief Commercial Officer The architect of STAAR's global refractive transformation returns to lead STAAR's next commercial chapter as EVO ICL outpaces a declining laser refractive market LAKE FOREST, C

Original reporting
SEC EDGAR 8-K
Published Sep 9, 2026, 9:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 10:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$STAA
Bullish
medium confidence
Mentioned
$STAA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$STAABullishLow
01

Why it matters

The appointment signals a strategic push to capture market share from declining laser refractive procedures, but short‑term price reaction may be muted.

02

Market read

Executive leadership change could influence STAAR's growth trajectory and sector sentiment, especially in Asia.

03

What to watch

Potential integration challenges and competition from emerging lens technologies could temper upside.

Relevance 6/10Novelty 6/10Timing: filing today

Background

STAAR Surgical (NASDAQ:STAA) is a leader in phakic intra‑ocular lenses, reporting an executive appointment via an 8‑K filing.

Company-level read

Ticker impact

$STAABullishMedium confidence
Context

SEC 8‑K reports appointment of former CEO David Bailey as Chief Commercial Officer, indicating strategic focus on ICL growth.

Expected impact

Modest upside potential as investors price in renewed leadership for growth.

Evidence & confidence

Bailey's prior success with ICL commercialization suggests execution strength, but impact may unfold over months.

Market effects

Sector

Reinforces bullish outlook for ophthalmic device sector as ICL adoption accelerates.

Regional

May benefit Asian markets where STAAR has strong presence.

Global

Highlights continued shift from laser to lens‑based refractive solutions worldwide.

Counterpoint

What could challenge this read

Executive changes rarely translate to immediate price moves; risk of over‑optimism on growth.

Key entities

  • Executive
    David Bailey

    Former President & CEO of STAAR, now Chief Commercial Officer.

  • Executive
    Warren Foust

    President & CEO of STAAR, overseeing the new appointment.

Read at source← All news

Related articles

SEP 26
$STAAHigh

Why Staar Surgical Stock Soared Today

Staar Surgical (NASDAQ: STAA) announced a $50 million share buyback program, anticipating it will last one year. The company's stock rose over 7% on Friday. CEO Warren Foust cited confidence in the business and strong financials, noting the company's undervaluation. Staar's recent Q2 results showed doubled net sales and a net profit, with $149 million in cash.

aol.com2 min
SEP 25
$STAAHigh

Staar Surgical Up 6% on $50M Share Buyback

Staar Surgical's board authorized a $50M share buyback, citing confidence in business progress and strong financials. The company reported $181.5M in cash and no debt as of July 3. Shares rose 6.3% to $20.28, with a $1B market cap.

ocbj.com1 min
SEP 15
$STAAMed

Is STAAR Surgical (STAA) A Bargain Following Its Profit Turnaround And China Led Sales Rebound?

STAAR Surgical (STAA) reported a 111% year-over-year increase in net sales to $93.5M, with China contributing over half. Net income turned positive at $8.1M. Despite this, the stock is down 11.88% over 30 days and 16.62% over a year. The company has no debt and significant cash reserves. Analysts suggest it may be undervalued with a fair value estimate of $29.67.

simplywall.st2 min
SEP 14
$STAAHigh

STAAR Surgical (STAA) Swings To Profit On China Rebound

STAAR Surgical (STAA) reported Q2 2026 net sales of $93.5M, up 111% YoY, with net income of $8.1M. China sales more than doubled to $52.3M, now over half of total revenue. CEO Warren Foust outlined plans for growth. Global sales rose 6% excluding China, and gross margin improved to 74.5%. The company ended the quarter with $181.5M in cash and no debt.

insidermonkey.com2 min
AUG 20
$STAAHighAI 8/10

STAAR (STAA) Q2 2026 Earnings Call Transcript

STAAR Surgical (STAA) reported Q2 2026 net sales of $93.5M, up 111% YoY, driven by China and Americas growth. Net income was $8.1M, or $0.16 per share, with adjusted EBITDA at $20.0M. Gross margin improved to 74.5%. Management highlighted EVO Plus success in China and U.S. market share gains, but noted risks from China tariffs and supply chain constraints.

fool.com3 min
AUG 17
$STAAMed

Why STAAR Surgical (STAA) Shares Are Sliding Today

STAAR Surgical (STAA) shares fell about 8% after Q2 results and sentiment cooled. The company reported sales and EPS above analysts’ estimates but cited uneven refractive market conditions and ongoing tariff and currency headwinds, especially in Asia. Stifel cut its price target to $28 from $31 (Hold) due to concerns about China. Shares closed at $24.15.

financialcontent.com4 min